@prefix : <http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl> .

<http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl> rdf:type owl:Ontology ;
                                                                              owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                              rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/312111"^^xsd:anyURI ;
                                                                              rdfs:label "Esomeprazole and gynaecomastia in obese adults"^^rdfs:Literal ;
                                                                              owl:versionInfo "draft-v0.95-20210520"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#refers_to_rechallenge_outcome
:refers_to_rechallenge_outcome rdf:type owl:DatatypeProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#BreastEnlargement
:BreastEnlargement rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N62" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006242 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Breast enlargement" ;
                   rdfs:label "Breast enlargement" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Discussion
:Discussion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Discussion> ;
            mp:references :Ref.10 ,
                          :Ref.11 ,
                          :Ref.4 ,
                          :Ref.5 ,
                          :Ref.6 ,
                          :Ref.7 ,
                          :Ref.8 ,
                          :Ref.9 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The series presented here is of six patients who developed breast enlargement. Five of them developed the gynaecomastia after taking esomeprazole and one after taking ranitidine for
7 1/2 years (he also received omeprazole and esomeprazole after gynaecomastia). Only two patients reported remission of the target symptom after esomeprazole withdrawal. The series is too small for statistical analysis, but an interesting factor is that esomeprazole and gynaecomastia was disproportionately overreported for obese adults but not for esomeprazole and gynaecomastia in general. Among the four subjects who did not present regression of the gynaecomastia, three were very obese (BMI>36), and two whose breast enlargements regressed had BMIs of 31.6 and 31.8.
Male obesity can often be associated with true gynaecomastia as this condition is caused by an imbalance between oestrogen action relative to androgen action at the breast tissue level. Increased extragonadal conversion of androgens to oestrogens by tissue aromatase, as occurs in obesity.4 However, sometimes adipose tissue accumulation at breast level can be mistaken for real gynaecomastia. This condition, particularly frequent in overweight subjects, takes the name of pseudo-gynaecomastia. Often gynaecomastia and pseudo-gynaecomastia are both present in the same subject at the same time.5
Patient 2 also received spironolactone, which has strongly been associated with gynaecomastia. Upon withdrawal of both drugs, the mammary enlargement regressed and did not recur, even when esomeprazole was re-introduced, but not spironolactone. It appears that spironolactone promotes gynaecomastia through the inhibition of 17-β hydroxysteroid dehydrogenase.6
Patient 5, with the lowest BMI (30.4), who had persistent enlarged breasts, had been taking
ranitidine for over 7 1/2 years. Ranitidine, like cimetidine, is a H2 histamine receptor blocker and one of the drug classes that has been implicated with gynaecomastia, with relative risk >7 for treated patients, and strongly dose-dependent.5
Omeprazole and its S-enantiomer esomeprazole at high concentrations appear to inhibit cytochrome P450 (CYP) 3A4 – which strongly catalyses the oxidation of estradiol, its major catabolic pathway – giving rise to an increase in estradiol levels.7 Omeprazole is extensively metabolised by CYP2C19, for which >15 variant alleles associated with a decreased metabolism have been identified (the frequency of poor metabolisers among Europeans ranges from 1% to 6% 8,9) and it is possible that such patients, when treated for long periods with higher doses of omeprazole, would be at particular risk for the development of gynaecomastia. For anti-histamines such as cimetidine, a similar mechanism mediated by CYP3A4, in combination with an androgenic receptor blockage, has been proposed.10
In VigiBase, the association of gynaecomastia and proton-pump inhibitors is disproportionately overreported for lansoprazole and omeprazole.
Furthermore, the association of esomeprazole and gynaecomastia appears to be quite significant, according to recent pharmacovigilance statistics presented in the United States (figure 1).11""" ;
            rdfs:label "Discussion" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Dose_for_report_5
:Dose_for_report_5 rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :omeprazole ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :interval_for_esomeprazol_for_report_5 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 20 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "20 mg" ;
                   rdfs:label "Dose of omeprazole for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Dose_of_esomeprazole_for_report_5
:Dose_of_esomeprazole_for_report_5 rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :interval_for_esomeprazole_for_report_5 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 20 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "20 mg" ;
                                   rdfs:label "Dose of esomeprazole for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Dr_Anthony_Wong
:Dr_Anthony_Wong rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Anthony" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Wong" ;
                 rdfs:label "Dr Anthony Wong" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Esomeprazole_and_gynaecomastia_in_obese_adults
:Esomeprazole_and_gynaecomastia_in_obese_adults rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Dr_Anthony_Wong ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :PV_signal ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/05/2019"^^xsd:date ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "Further investigation needed" ;
                                                rdfs:label "Esomeprazole and gynaecomastia in obese adults" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#GERD
:GERD rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K21.9" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10017885 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Gastrooesophageal reflux disease" ;
      rdfs:label "GERD" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#GastricPain
:GastricPain rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R1010" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000087 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Abdominal pain upper" ;
             rdfs:label "Gastric pain" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#GastroesophagealReflux
:GastroesophagealReflux rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K21.9" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10017885 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Gastrooesophageal reflux disease" ;
                        rdfs:label "Gastroesophageal reflux" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Gynecomastia
:Gynecomastia rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N62" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10018800 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Gynaecomastia" ;
              rdfs:label "Gynecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#HaemorrhageOfDigestiveTract
:HaemorrhageOfDigestiveTract rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K922" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10017955 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Gastrointestinal haemorrhage" ;
                             rdfs:label "Haemorrhage of digestive tract" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#HeartFailure
:HeartFailure rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007554 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac failure" ;
              rdfs:label "Heart failure" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#HelicobacterDuodenalUlcer
:HelicobacterDuodenalUlcer rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K26.9" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10081255 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Helicobacter duodenal ulcer" ;
                           rdfs:label "Helicobacter duodenal ulcer" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#InfoForPatient1
:InfoForPatient1 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "An adult male obese patient (BMI=36.2), age not given, had taken esomeprazole for gastroesophageal reflux and diclofenac for pain during an unknown period. He presented enlargement after an unstated time. He did not smoke and reported very little alcohol consumption. There was no reference as to follow-up nor whether the breast enlargement was resolved." ;
                 rdfs:label "Info for patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#InfoForPatient2
:InfoForPatient2 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A 77-year old slightly obese man (BMI=31.6) was taking esomeprazole (between January and August 2016) for haemorrhage of digestive tract and spironolactone for heart failure. Breast enlargement was noted in July, so both drugs were suspended in early August and the problem resolved. However, due to a recurrence of gastric symptoms, esomeprazole was reintroduced at the end of the same month. Breast enlargement did not recur. There is no mention that spironolactone was also added to his regimen." ;
                 rdfs:label "Info for patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Initial_dose_for_report_4
:Initial_dose_for_report_4 rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 20 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "20 mg" ;
                           rdfs:label "Initial dose for report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.2 ,
                                        :Ref.3 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Gynaecomastia is stated as an adverse reaction for esomeprazole in both the United States (US) Food and Drug Administration (FDA) label and in the United Kingdom (UK) Summary of Product Characteristics (SmPC). However, obesity is not described as a risk group for this drug-induced gynaecomastia in either source.2,3" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Mechanism_of_esomeprazole
:Mechanism_of_esomeprazole rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                           mp:references :Ref.2 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Esomeprazole is a proton-pump inhibitor used to treat gastroesophageal reflux disease (GERD), helicobacter pylori-associated ulcers in combination with antibiotics, as well as to treat and prevent NSAID-associated ulcers. It acts by inhibiting the enzyme H+K+-ATPase and thus inhibits both basal and stimulated acid secretion" ;
                           rdfs:label "Mechanism of esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Obesity
:Obesity rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E669" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10029883 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Obesity" ;
         rdfs:label "Obesity" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#PV_signal
:PV_signal rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Pathophysiology_of_gynaecomastia ,
                                                                                       :Reports_in_Vigibase ,
                                                                                       :conclusion ,
                                                                                       :introduction ,
                                                                                       :summary ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                  :Report2 ,
                                                                                                  :Report3 ,
                                                                                                  :Report4 ,
                                                                                                  :Report5 ,
                                                                                                  :Report6 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :reportsForEsomeprazoleAndGynaecomastia ,
                                                                                              :reportsForEsomeprazoleAndGynaecomastiaInObeseAdults ,
                                                                                              :reportsWithPositiveDechallenge ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
           mp:supportedByData :gynaecomastia_and_PPIs ,
                              :male_obesity_as_a_confounder ,
                              :ranitidine_as_a_confounder ,
                              :spironolactone_as_a_confounder ,
                              <http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#United_States_(US)_Food__and_Drug_Administration_(FDA)_label_and_in_the__United_Kingdom_(UK)_Summary_of_Product__Characteristics_(SmPC)_for_esomeprazole> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/05/2019" ;
           rdfs:label "PV signal" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Pain
:Pain rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G891" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033371 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pain" ;
      rdfs:label "Pain" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Pathophysiology_of_gynaecomastia
:Pathophysiology_of_gynaecomastia rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :introduction ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                  mp:references :Ref.1 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Gynaecomastia is the abnormal swelling of the  mammary glands in males and can be either  physiological, metabolic, idiopathic, pharmacologic  or iatrogenic in cause. Mammary glandular tissue  proliferation is physiologically stimulated by  oestrogens and inhibited by androgens.  Gynaecomastia is usually the result of the increased  ratio of free-circulating oestrogens/androgens or  their altered effects on their correspondent  intracellular receptors in mammary tissue.  The majority of gynaecomastia cases have  physiologic causes (neonatal, pubertal and senile  gynaecomastia). About a quarter can be idiopathic  or secondary to pathologies affecting levels of  circulating sexual hormones (i.e. testicular or  adrenal neoplasias, hepatic cirrhosis,  hyperthyroidism, hypogonadism, obesity, refeeding  syndrome). A consistent proportion of cases (20%)  is iatrogenic in origin, including pharmacologic, from  hormone supplementation or adverse drug effects.  Among these are exogenous oestrogens, anti-androgens, 5-alpha-reductase inhibitors, spironolactone and antiulcer drugs (cimetidine, 
proton-pump inhibitors).1""" ;
                                  rdfs:label "Pathophysiology of gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 77 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 51 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 61 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 60 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 43 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#ProphylaxisOfNSAIDGastricUlceration
:ProphylaxisOfNSAIDGastricUlceration rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K27.9" ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10054981 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Prophylaxis against gastrointestinal ulcer" ;
                                     rdfs:label "Prophylaxis of NSAID gastric ulceration" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Pyrosis
:Pyrosis rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K30" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013946 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dyspepsia" ;
         rdfs:label "Pyrosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Meyboom, RH et al. Proton-pump inhibitors and gynecomastia. Nederlands Bijwerkingen Centrum Lareb, August 2005." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Lardinois CK, Mazzaferri EL. Cimetidine blocks testosterone synthesis. Arch Intern Med. 1985;145(5):920-2." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Nexium and Gynaecomastia - from FDA reports [histogram]. 2018. Available from: https://www.ehealthme.com/ds/nexium/gynae comastia/. Accessed: 2018-01-30." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "electronic Medicines Compendium: Summary of Product Characteristics for esomeprazole (Emozul®). Available from: https://www.medicines.org.uk/emc/product/47 27. Accessed: 2018-03-29." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "US Food and Drug Administration: Product label for esomeprazole (Nexium®). Available from: https://dailymed.nlm.nih.gov/dailymed/drugIn fo. cfm?setid=f4853677-1622-4037-688b- fdf533a11d96. Accessed: 2018-03-29." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Johnson RE, Murad MH. Gynecomastia: Pathology, Evaluation and Management. Mayo Clin Proc. 2009;84(11):1010-15." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Roberto G, Melis M, Biagi C. Drug-induced gynecomastia. Focus Farmacovigilanza. 2013;77(7):2." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Satoh T, Munakata H, Fujita K, Itoh S, Kamataki T, Yoshizawa I. Studies on the interactions between drug and estrogen: II. On the inhibitory effect of 29 drugs reported to induced gynaecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull. 2003;26(5):695-700." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Carvajal A, Macias D, Gutierrez A, Ortega S, Sáinz M, Martín Arias LH, et al. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System. Drug Saf. 2007;30(6):527-31." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-58." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastroesophagealReflux ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InfoForPatient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :BreastEnlargement ,
                                                                                  :Gynecomastia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :diclofenac ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :InfoForPatient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :BreastEnlargement ,
                                                                                  :Gynecomastia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :spironolactone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :esomeprazole_usage_for_report_2 ,
                                                                                       :spironolactone_usage_for_report_2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :durationOfEsomeprazoletreatment-report2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "negative rechallenge - condition not appeared" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :infoForPatient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :hydroclorothiazide ,
                                                                                    :lercadipine ,
                                                                                    :tramadol ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :report_3_usage_lercanidipine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :durationOfEsomeprazoletreatment-report3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "negative - condition still applied" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastricPain ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :infoForPatient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ,
                                                                                  :Pain ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :amlodipine ,
                                                                                    :diclofenac ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :esomeprazole_usage_for_Report4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :duration_of_esomeprazole_for_report_5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :infoForPatient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :esomeprazole_usage_for_report_5 ,
                                                                                       :ranitidine_usage_for_report_5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :omeprazole ,
                                                                                          :ranitidine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastroesophagealReflux ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :infoForPatient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :BreastEnlargement ,
                                                                                  :Gynecomastia ,
                                                                                  :decreased_libido ,
                                                                                  :partial_erectile_difficulty ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :esomeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :report_6_esomeprazole_usage ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "negative - condition still applied" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """In a screening of VigiBase, the WHO global database of individual case safety reports, esomeprazole and gynaecomastia was found to be disproportionately overreported in obese adults (BMI>30). The observed number of reports was 6 compared to 0.6 expected. For esomeprazole and gynaecomastia in general, the observed number of reports was 92 and the expected 80. The present commentary is on the six cases reporting the possible association of esomeprazole, a proton- pump inhibitor and the occurrence of gynaecomastia in obese adults. The cases were retrieved from VigiBase on 10 January 2018, and were as follows:
1.	An adult male obese patient (BMI=36.2), age not given, had taken esomeprazole for gastroesophageal reflux and diclofenac for pain during an unknown period. He presented enlargement after an unstated time. He did not smoke and reported very little alcohol consumption. There was no reference as to follow-up nor whether the breast enlargement was resolved.
2.	A 77-year old slightly obese man (BMI=31.6) was taking esomeprazole (between January and August 2016) for haemorrhage of digestive tract and spironolactone for heart failure. Breast enlargement was noted in July, so both drugs were suspended in early August and the problem resolved. However, due to a recurrence of gastric symptoms, esomeprazole was reintroduced at the end of the same month. Breast enlargement did not recur. There is no mention that spironolactone was also added to his regimen.
3.	A 51-year old male, very obese (BMI=41.3), received esomeprazole for two years and lercanidipine for five years, as well as hydrochlorothiazide and tramadol for unspecified periods. He developed left breast enlargement after taking the drugs for several years. A mammogram showed an apparently normal well-developed breast, without adenopathy. The enlargement persisted despite dechallenge and rechallenge of esomeprazole and lercanidipine.
4.	A 61-year old slightly obese male patient (BMI=31.8), with non-Hodgkin B type lymphoma (stage 4) with multiple adenopathies and obstructive renal insufficiency (urethral infiltration), who had been a heavy smoker, was prescribed esomeprazole, amlodipine and diclofenac. He received esomeprazole 20 mg due to gastric pain and gastroesophageal reflux, and had the dose doubled to 40 mg after three days. Two days later, he developed pain and enlargement of both breasts. The gynaecomastia regressed within four weeks.
Hormone levels were not checked.
5.	A 60-year old male (BMI=30.4), with sarcoidosis and pyrosis, who had been taking
ranitidine for over 7 1/2 years, switched to omeprazole (20 mg twice a day) for seven months and then esomeprazole (20 mg twice a day). He developed breast enlargement when on ranitidine, so one month later he began taking omeprazole and later switched to esomeprazole. Gynaecomastia persisted even after the switches.
6.	A 43-year old very obese male (BMI=39.0) received esomeprazole for five months for gastroesophageal reflux. Soon after, he reported decreased libido, partial erectile difficulty and breast enlargement. After discontinuation of the drug, he recovered erection and libido, but gynaecomastia persisted.""" ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Sarcoidosis
:Sarcoidosis rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D86.9" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039486 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Sarcoidosis" ;
             rdfs:label "Sarcoidosis" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Second_dose_for_report_4
:Second_dose_for_report_4 rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 40 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "40 mg" ;
                          rdfs:label "Second dose for report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#Usage_of_esomeprazole
:Usage_of_esomeprazole rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GERD ,
                                                                                                   :HelicobacterDuodenalUlcer ,
                                                                                                   :ProphylaxisOfNSAIDGastricUlceration ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                       rdfs:label "usage of esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07FB07" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#cimetidine
:cimetidine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :cimetidineTriggeringGynaecomastia ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BA01" ;
            rdfs:label "cimetidine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#cimetidineTriggeringGynaecomastia
:cimetidineTriggeringGynaecomastia rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                   mp:references :Ref.10 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "For anti-histamines such as cimetidine, a similar mechanism mediated by CYP3A4, in combination with an androgenic receptor blockage, has been proposed.10" ;
                                   rdfs:comment "I am trying to link the mechanism of AE with the drug is this way (using object property assertion from here). Alternatively, we could go to Drug and the use a property assertion refering to mechanism." ;
                                   rdfs:label "cimetidine triggering gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Esomeprazole is known to cause gynaecomastia, as stated in the label. Their metabolic pathway appears to catalyse oxidation of estradiol, thereby increasing estradiol levels, and is strongly dose dependent. In this particular series, all six patients with gynaecomastia were obese, whereas the breast enlargement regressed upon removal of esomeprazole in the two mildly obese patients, but not in the remaining four very obese patients.
Obesity is often associated with increased oestrogen due to extragonadal conversion from androgen by tissue aromatase and since esomeprazole is known to cause gynaecomastia, this can have an additive effect. There are also indications of the reaction being more difficult to reverse. However, since this is a small case series, a more extensive review is needed.""" ;
            rdfs:label "conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#decreased_libido
:decreased_libido rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R68.82" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024419 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Libido decreased" ;
                  rdfs:label "decreased libido" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#diclofenac
:diclofenac rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01AB05" ;
            rdfs:label "diclofenac" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#diclofenac_usage_for_report_1
:diclofenac_usage_for_report_1 rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Pain ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :diclofenac ;
                               rdfs:label "report 1 diclofenac usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#durationOfEsomeprazoletreatment-report2
:durationOfEsomeprazoletreatment-report2 rdf:type owl:NamedIndividual ,
                                                  <http://www.w3.org/2006/time#DurationDescription> ;
                                         <http://www.w3.org/2006/time#nominalPosition> "months" ;
                                         <http://www.w3.org/2006/time#numericPosition> 8 ;
                                         rdfs:label "duration of esomeprazole treatment-report 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#durationOfEsomeprazoletreatment-report3
:durationOfEsomeprazoletreatment-report3 rdf:type owl:NamedIndividual ,
                                                  <http://www.w3.org/2006/time#DurationDescription> ;
                                         <http://www.w3.org/2006/time#nominalPosition> "years" ;
                                         <http://www.w3.org/2006/time#numericPosition> 2 ;
                                         rdfs:label "duration of esomeprazole treatment-report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#durationOfOmeprazoletreatment-report4
:durationOfOmeprazoletreatment-report4 rdf:type owl:NamedIndividual ,
                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                       <http://www.w3.org/2006/time#nominalPosition> "months" ;
                                       <http://www.w3.org/2006/time#numericPosition> 7 ;
                                       rdfs:label "duration of omeprazole treatment-report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#durationOfRanitidinetreatment-report4
:durationOfRanitidinetreatment-report4 rdf:type owl:NamedIndividual ,
                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                       <http://www.w3.org/2006/time#nominalPosition> "years" ;
                                       <http://www.w3.org/2006/time#numericPosition> 7.5 ;
                                       rdfs:label "duration of ranitidine treatment-report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#duration_of_esomeprazole_for_report_5
:duration_of_esomeprazole_for_report_5 rdf:type owl:NamedIndividual ,
                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                       <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                       <http://www.w3.org/2006/time#numericPosition> 5 ;
                                       rdfs:label "duration of esomeprazole treatment-report 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#duration_of_esomeprazole_treatment-report_6
:duration_of_esomeprazole_treatment-report_6 rdf:type owl:NamedIndividual ,
                                                      <http://www.w3.org/2006/time#DurationDescription> ;
                                             <http://www.w3.org/2006/time#nominalPosition> "months" ;
                                             <http://www.w3.org/2006/time#numericPosition> 5 ;
                                             rdfs:label "duration of esomeprazole treatment-report 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#duration_of_lercanidipine
:duration_of_lercanidipine rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/2006/time#DurationDescription> ;
                           <http://www.w3.org/2006/time#nominalPosition> "years" ;
                           <http://www.w3.org/2006/time#numericPosition> 5 ;
                           rdfs:label "duration of lercanidipine treatment-report 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazole
:esomeprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_esomeprazole ,
                                                                            :esomeprazoleTriggeringGynaecomastia ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC05" ;
              rdfs:label "esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazoleTriggeringGynaecomastia
:esomeprazoleTriggeringGynaecomastia rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                     mp:references :Ref.7 ,
                                                   :Ref.8 ,
                                                   :Ref.9 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Omeprazole and its S-enantiomer esomeprazole at high concentrations appear to inhibit cytochrome P450 (CYP) 3A4 – which strongly catalyses the oxidation of estradiol, its major catabolic pathway – giving rise to an increase in estradiol levels.7 Omeprazole is extensively metabolised by CYP2C19, for which >15 variant alleles associated with a decreased metabolism have been identified (the frequency of poor metabolisers among Europeans ranges from 1% to 6% 8,9) and it is possible that such patients, when treated for long periods with higher doses of omeprazole, would be at particular risk for the development of gynaecomastia.
Esomeprazole is known to cause gynaecomastia, as stated in the label. Their metabolic pathway appears to catalyse oxidation of estradiol, thereby increasing estradiol levels, and is strongly dose dependent. In this particular series, all six patients with gynaecomastia were obese, whereas the breast enlargement regressed upon removal of esomeprazole in the two mildly obese patients, but not in the remaining four very obese patients.""" ;
                                     rdfs:label "esomeprazole triggering gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazole_usage_for_Report4
:esomeprazole_usage_for_Report4 rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastricPain ,
                                                                                                            :GastroesophagealReflux ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :Initial_dose_for_report_4 ,
                                                                                                 :Second_dose_for_report_4 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                rdfs:label "report 4 esomeprazole usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazole_usage_for_report_1
:esomeprazole_usage_for_report_1 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastroesophagealReflux ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                 rdfs:label "report 1 esomeprazole usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazole_usage_for_report_2
:esomeprazole_usage_for_report_2 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :HaemorrhageOfDigestiveTract ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                 rdfs:label "report 2 esomeprazole usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#esomeprazole_usage_for_report_5
:esomeprazole_usage_for_report_5 rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Pyrosis ,
                                                                                                             :Sarcoidosis ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :Dose_for_report_5 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                 rdfs:label "report 5 omeprazole usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#gynaecomastia_and_PPIs
:gynaecomastia_and_PPIs rdf:type owl:NamedIndividual ,
                                 <http://purl.obolibrary.org/obo/OAE_0001197> ;
                        mp:references :Ref.11 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In VigiBase, the association of gynaecomastia and proton-pump inhibitors is disproportionately overreported for lansoprazole and omeprazole." ;
                        rdfs:label "gynaecomastia and PPIs" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#hydroclorothiazide
:hydroclorothiazide rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03AA03" ;
                    rdfs:label "hydrochlorothiazide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#infoForPatient3
:infoForPatient3 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A 51-year old male, very obese (BMI=41.3), received esomeprazole for two years and lercanidipine for five years, as well as hydrochlorothiazide and tramadol for unspecified periods. He developed left breast enlargement after taking the drugs for several years. A mammogram showed an apparently normal well-developed breast, without adenopathy. The enlargement persisted despite dechallenge and rechallenge of esomeprazole and lercanidipine." ;
                 rdfs:label "info for patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#infoForPatient4
:infoForPatient4 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """A 61-year old slightly obese male patient (BMI=31.8), with non-Hodgkin B type lymphoma (stage 4) with multiple adenopathies and obstructive renal insufficiency (urethral infiltration), who had been a heavy smoker, was prescribed esomeprazole, amlodipine and diclofenac. He received esomeprazole 20 mg due to gastric pain and gastroesophageal reflux, and had the dose doubled to 40 mg after three days. Two days later, he developed pain and enlargement of both breasts. The gynaecomastia regressed within four weeks.
Hormone levels were not checked.""" ;
                 rdfs:label "info for patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#infoForPatient5
:infoForPatient5 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A 60-year old male (BMI=30.4), with sarcoidosis and pyrosis, who had been taking ranitidine for over 7 1/2 years, switched to omeprazole (20 mg twice a day) for seven months and then esomeprazole (20 mg twice a day). He developed breast enlargement when on ranitidine, so one month later he began taking omeprazole and later switched to esomeprazole. Gynaecomastia persisted even after the switches." ;
                 rdfs:label "info for patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#infoForPatient6
:infoForPatient6 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A 43-year old very obese male (BMI=39.0) received esomeprazole for five months for gastroesophageal reflux. Soon after, he reported decreased libido, partial erectile difficulty and breast enlargement. After discontinuation of the drug, he recovered erection and libido, but gynaecomastia persisted." ;
                 rdfs:label "info for patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#interval_for_esomeprazol_for_report_5
:interval_for_esomeprazol_for_report_5 rdf:type owl:NamedIndividual ,
                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                       <http://www.w3.org/2006/time#nominalPosition> "hours" ;
                                       <http://www.w3.org/2006/time#numericPosition> 12 ;
                                       rdfs:label "interval for omeprazole for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#interval_for_esomeprazole_for_report_5
:interval_for_esomeprazole_for_report_5 rdf:type owl:NamedIndividual ,
                                                 <http://www.w3.org/2006/time#DurationDescription> ;
                                        <http://www.w3.org/2006/time#nominalPosition> "hours" ;
                                        <http://www.w3.org/2006/time#numericPosition> 12 ;
                                        rdfs:label "interval for esomeprazole for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Gynaecomastia is the abnormal swelling of the mammary glands in males and can be either physiological, metabolic, idiopathic, pharmacologic or iatrogenic in cause. Mammary glandular tissue proliferation is physiologically stimulated by oestrogens and inhibited by androgens.
Gynaecomastia is usually the result of the increased ratio of free-circulating oestrogens/androgens or their altered effects on their correspondent intracellular receptors in mammary tissue.
The majority of gynaecomastia cases have physiologic causes (neonatal, pubertal and senile gynaecomastia). About a quarter can be idiopathic or secondary to pathologies affecting levels of circulating sexual hormones (i.e. testicular or adrenal neoplasias, hepatic cirrhosis, hyperthyroidism, hypogonadism, obesity, refeeding syndrome). A consistent proportion of cases (20%) is iatrogenic in origin, including pharmacologic, from hormone supplementation or adverse drug effects. Among these are exogenous oestrogens, anti-androgens, 5-alpha-reductase inhibitors, spironolactone and antiulcer drugs (cimetidine, proton-pump inhibitors).1
Esomeprazole is a proton-pump inhibitor used to treat gastroesophageal reflux disease (GERD), helicobacter pylori-associated ulcers in combination with antibiotics, as well as to treat and prevent NSAID-associated ulcers. It acts by inhibiting the enzyme H+K+-ATPase and thus inhibits both basal and stimulated acid secretion.2""" ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#lercadipine
:lercadipine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA13" ;
             rdfs:label "lercadipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#male_obesity_as_a_confounder
:male_obesity_as_a_confounder rdf:type owl:NamedIndividual ,
                                       <http://purl.obolibrary.org/obo/OAE_0001182> ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                              mp:references :Ref.4 ,
                                            :Ref.5 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Male obesity can often be associated with true gynaecomastia as this condition is caused by an imbalance between oestrogen action relative to androgen action at the breast tissue level. Increased extragonadal conversion of androgens to oestrogens by tissue aromatHowever, sometimes adipose tissue accumulation at breast level can be mistaken for real gynaecomastia. This condition, particularly frequent in overweight subjects, takes the name of pseudo-gynaecomastia. Often gynaecomastia and pseudo-gynaecomastia are both present in the same subject at the same time.5ase, as occurs in obesity.4" ;
                              rdfs:label "male obesity as a confounder" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#omeprazole
:omeprazole rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC01" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#omeprazoleTriggeringGynaecomastia
:omeprazoleTriggeringGynaecomastia rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :omeprazole ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                   mp:references :Ref.7 ,
                                                 :Ref.8 ,
                                                 :Ref.9 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Omeprazole and its S-enantiomer esomeprazole at high concentrations appear to inhibit cytochrome P450 (CYP) 3A4 – which strongly catalyses the oxidation of estradiol, its major catabolic pathway – giving rise to an increase in estradiol levels.7 Omeprazole is extensively metabolised by CYP2C19, for which >15 variant alleles associated with a decreased metabolism have been identified (the frequency of poor metabolisers among Europeans ranges from 1% to 6% 8,9) and it is possible that such patients, when treated for long periods with higher doses of omeprazole, would be at particular risk for the development of gynaecomastia." ;
                                   rdfs:label "omeprazole triggering gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#partial_erectile_difficulty
:partial_erectile_difficulty rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N52. 9" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061461 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Erectile dysfunction" ;
                             rdfs:label "partial erectile difficulty" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#ranitidine
:ranitidine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :ranitidineTriggeringGynaecomastia ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BA02" ;
            rdfs:label "ranitidine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#ranitidineTriggeringGynaecomastia
:ranitidineTriggeringGynaecomastia rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                   mp:references :Ref.5 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Patient 5, with the lowest BMI (30.4), who had persistent enlarged breasts, had been taking
ranitidine for over 7 1/2 years. Ranitidine, like cimetidine, is a H2 histamine receptor blocker and one of the drug classes that has been implicated with gynaecomastia, with relative risk >7 for treated patients, and strongly dose-dependent.5""" ;
                                   rdfs:label "ranitidine triggering gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#ranitidine_as_a_confounder
:ranitidine_as_a_confounder rdf:type owl:NamedIndividual ,
                                     <http://purl.obolibrary.org/obo/OAE_0001182> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :ranitidine ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                            mp:references :Ref.5 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Patient 5, with the lowest BMI (30.4), who had persistent enlarged breasts, had been taking ranitidine for over 7 1/2 years. Ranitidine, like cimetidine, is a H2 histamine receptor blocker and one of the drug classes that has been implicated with gynaecomastia, with relative risk >7 for treated patients, and strongly dose-dependent.5" ;
                            rdfs:label "ranitidine as a confounder" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#ranitidine_usage_for_report_5
:ranitidine_usage_for_report_5 rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Pyrosis ,
                                                                                                           :Sarcoidosis ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ranitidine ;
                               <http://www.w3.org/2006/time#hasDurationDescription> :durationOfRanitidinetreatment-report4 ;
                               rdfs:label "report 5 ranitidine usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#report_3_usage_lercanidipine
:report_3_usage_lercanidipine rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :lercadipine ;
                              <http://www.w3.org/2006/time#hasDurationDescription> :duration_of_lercanidipine ;
                              rdfs:label "report 3 usage lercanidipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#report_6_esomeprazole_usage
:report_6_esomeprazole_usage rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :GastroesophagealReflux ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                             <http://www.w3.org/2006/time#hasDurationDescription> :duration_of_esomeprazole_treatment-report_6 ;
                             rdfs:label "report 6 esomeprazole usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#reportsForEsomeprazoleAndGynaecomastia
:reportsForEsomeprazoleAndGynaecomastia rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 92 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_expected_count> "80.0"^^xsd:float ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "reports for esomeprazole and gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#reportsForEsomeprazoleAndGynaecomastiaInObeseAdults
:reportsForEsomeprazoleAndGynaecomastiaInObeseAdults rdf:type owl:NamedIndividual ,
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Obesity ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsForEsomeprazoleAndGynaecomastia ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_expected_count> "0.6"^^xsd:float ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                     rdfs:label "reports for esomeprazole and gynaecomastia in obese adults" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#reportsWithPositiveDechallenge
:reportsWithPositiveDechallenge rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsForEsomeprazoleAndGynaecomastiaInObeseAdults ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
                                rdfs:label "reports with positive dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#spironolactone
:spironolactone rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :spironolactoneTriggeringGynaecomastia ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03DA01" ;
                rdfs:label "spironolactone" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#spironolactoneTriggeringGynaecomastia
:spironolactoneTriggeringGynaecomastia rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                       mp:references :Ref.6 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Patient 2 also received spironolactone, which has strongly been associated with gynaecomastia. Upon withdrawal of both drugs, the mammary enlargement regressed and did not recur, even when esomeprazole was re-introduced, but not spironolactone. It appears that spironolactone promotes gynaecomastia through the inhibition of 17-β hydroxysteroid dehydrogenase.6" ;
                                       rdfs:label "spironolactone triggering gynaecomastia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#spironolactone_as_a_confounder
:spironolactone_as_a_confounder rdf:type owl:NamedIndividual ,
                                         <http://purl.obolibrary.org/obo/OAE_0001182> ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :spironolactone ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                mp:references :Ref.6 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Patient 2 also received spironolactone, which has strongly been associated with gynaecomastia. Upon withdrawal of both drugs, the mammary enlargement regressed and did not recur, even when esomeprazole was re-introduced, but not spironolactone. It appears that spironolactone promotes gynaecomastia through the inhibition of 17-β hydroxysteroid dehydrogenase.6" ;
                                rdfs:label "spironolactone as a confounder" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#spironolactone_usage_for_report_2
:spironolactone_usage_for_report_2 rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :HeartFailure ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :spironolactone ;
                                   rdfs:label "report 2 spironolactone usage" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Gynaecomastia is the abnormal swelling of the mammary glands in males and the causes can be physiological, metabolic, idiopathic, pharmacologic or iatrogenic. About a quarter of cases can be idiopathic or secondary to pathologies affecting levels of circulating sexual hormones. A consistent proportion of cases (20%) is iatrogenic in origin, including pharmacologic, from hormone supplementation or adverse drug effects. Among these are exogenous oestrogens, anti-androgens, 5-alpha-reductase inhibitors, spironolactone and antiulcer drugs (cimetidine, proton-pump inhibitors). Gynaecomastia is stated as an adverse
reaction for esomeprazole in both the United States
(US) Food and Drug Administration (FDA) label and in the United Kingdom (UK) Summary of Product Characteristics (SmPC). However, obesity is not described as a risk group for this drug-induced gynaecomastia. In a screening of VigiBase, the WHO global database of individual case safety reports, esomeprazole and gynaecomastia was found to be disproportionately overreported in obese adults (BMI>30). The observed number of reports was 6 compared to 0.6 expected. For esomeprazole and gynaecomastia in general, the observed number of reports was 92 and the expected 80. The series presented here is of the six obese patients who developed breast enlargement. Five of them experienced the gynaecomastia after taking esomeprazole and one after taking ranitidine
for 7 1/2 years. Only two patients reported remission of the target symptom after esomeprazole withdrawal. Among the four subjects who did not present regression of the gynaecomastia, three were very obese (BMI>36), and two whose breast enlargements regressed had BMIs of 31.6 and 31.8. Obesity is often associated with increased oestrogen due to extragonadal conversion from androgen by tissue aromatase and since esomeprazole is known to cause gynaecomastia, this can have an additive effect.
There are also indications of the reaction being more difficult to reverse. However, since this is a small case series, a more extensive review is needed.""" ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#tramadol
:tramadol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AX02" ;
          rdfs:label "tramadol" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#United_States_(US)_Food__and_Drug_Administration_(FDA)_label_and_in_the__United_Kingdom_(UK)_Summary_of_Product__Characteristics_(SmPC)_for_esomeprazole
<http://purl.org/OpenPVSignal/Signals/2019_2_esomeprazole_gynaecomastia.owl#United_States_(US)_Food__and_Drug_Administration_(FDA)_label_and_in_the__United_Kingdom_(UK)_Summary_of_Product__Characteristics_(SmPC)_for_esomeprazole> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                                                                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                                                                                                                                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Gynecomastia ;
                                                                                                                                                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :esomeprazole ;
                                                                                                                                                                                                                                      mp:references :Ref.2 ,
                                                                                                                                                                                                                                                    :Ref.3 ;
                                                                                                                                                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Gynaecomastia is stated as an adverse reaction for esomeprazole in both the United States (US) Food and Drug Administration (FDA) label and in the United Kingdom (UK) Summary of Product Characteristics (SmPC). However, obesity is not described as a risk group for this drug-induced gynaecomastia in either source.2,3" ;
                                                                                                                                                                                                                                      rdfs:label "US FDA label and UK SmPC for esomeprazole" ,
                                                                                                                                                                                                                                                 "United States (US) Food  and Drug Administration (FDA) label and in the  United Kingdom (UK) Summary of Product  Characteristics (SmPC) for esomeprazole" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
